Table 3 Scenario analyses for nivolumab vs everolimus
Nivolumab vs everolimus | Independent Weibull OS curves | Dependent log-logistic OS curve | Independent 2-knot spline hazard curves fitted to nivolumab and everolimus PFS data | Nivolumab TTD curve is used as a proxy for PFS | Ascribed doses of nivolumab |
|---|---|---|---|---|---|
Incremental cost per QALY gained, $US | 80,439 | 49,827 | 53,273 | 99,574 | 55,591 |
Incremental cost per LYG, $US | 71,697 | 42,866 | 45,963 | 87,391 | 47,917 |
Incremental costs, $US | 31,457 | 33,138 | 34,219 | 65,062 | 35,674 |
Incremental QALYs | 0.39 | 0.67 | 0.64 | 0.65 | 0.64 |
Median OS nivolumab/everolimus, months | 26.3/20.4 | 26.0/19.1 | 26.0/19.4 | 26.0/19.4 | 26.0/19.4 |
Mean OS nivolumab/everolimus, months | 34.0/28.3 | 50.9/39.5 | 45.5/34.8 | 45.5/34.8 | 45.5/34.8 |